AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$ASPE

Aspen Neuroscience prices IPO at $15 per share on Nasdaq

Aspen Neuroscience (ASPE) priced its IPO at $15 per share, raising $140.6M from 9.375M shares. Underwriters have a 30-day option for additional shares. Trading begins Oct. 30, 2026, on Nasdaq. The company develops cell therapies for Parkinson’s disease.

Original reporting
investing.com
Published Oct 30, 2026, 2:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefIPO
Primary signal
$ASPE
Bearish
high confidence
Mentioned
$ASPE
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ASPEBearishHigh
01

Why it matters

The $140 M capital raise provides runway for trials but also introduces market pressure to meet milestones.

02

Market read

First‑report IPO adds a new biotech ticker, creating short‑term trading opportunities around debut pricing.

03

What to watch

Potential regulatory hurdles for iPSC therapy and competition from larger neuro‑degeneration players.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Aspen Neuroscience is a clinical‑stage company developing an iPSC‑based cell therapy for Parkinson's disease.

Company-level read

Ticker impact

$ASPEBearishHigh confidence
Context

Aspen Neuroscience announced pricing its IPO at $15 per share, raising about $140.6 million.

Expected impact

potential volatility with upside as the market prices in the fresh capital and pipeline prospects

Evidence & confidence

First‑report of a sizable IPO; capital raise >$100 M and a clinical‑stage biotech typically draws speculative buying.

Market effects

Sector

Adds a new listed biotech, may lift sector sentiment on Parkinson's‑therapy space.

Regional

Boosts Nasdaq biotech listings in the US market.

Global

Limited to US investors; modest global ripple.

Counterpoint

What could challenge this read

The IPO price may be overvalued given early‑stage clinical risk; short‑term pullback possible.

Key entities

  • company
    Aspen Neuroscience, Inc.

    Biotech firm pricing its IPO at $15 per share.

  • underwriter
    Leerink Partners

    Joint bookrunning manager for the offering.

Read at source← All news

StoryAspen Neuroscience prices Parkinson’s cell-therapy IPO

Also covered by

6 outlets

Related articles

OCT 30
$ASPEHighAI 9/10

Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s

Aspen Neuroscience raised $140.6M in its IPO, selling 9.4M shares at $15 each. The company's cell therapy, sasineprocel, aims to treat Parkinson's by replenishing dopamine-producing neurons. It will trade under 'ASPE'. Early trial data showed potential improvements and a favorable safety profile. Long-term data is expected in 2028, with a Phase 3 study planned by the end of 2024. Aspen claims its personalized approach could be safer and more effective than donor-derived therapies.

finance.yahoo.com2 min
OCT 30
$ASPEHighAI 9/10

Aspen Neuroscience prices IPO at $15 per share

Aspen Neuroscience (ASPE) priced its IPO at $15 per share, offering 9.375 million shares for gross proceeds of $140.6 million. The biotech company focuses on Parkinson's disease treatments. Shares began trading on Nasdaq under ASPE. Underwriters have a 30-day option for additional shares. The offering is expected to close November 2, 2026.

investing.com1 min
OCT 30
$ASPEHighAI 8/10

A Parkinson’s cell-therapy company expects about $140.6 million from its share sale, before costs.

Aspen Neuroscience, Inc. (Nasdaq: ASPE) announced its initial public offering of 9,375,000 shares at $14.95 per share, expected to raise $140.6 million before costs. Trading is set to begin on October 30, 2026, under the ticker ASPE. The offering is expected to close on November 2, 2026. The company focuses on developing autologous cell therapies for Parkinson's disease.

stocktitan.net2 min